To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03703050
Title Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)
Acronym NIVO-ALCL
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications
Therapies
Age Groups: adult | child | senior
Covered Countries GBR | FRA | DNK

Facility Status City State Zip Country Details
Rigshospitalet Copenhagen Denmark Details
Gustave Roussy Villejuif Val De Marne 94805 France Details
CHU Bordeaux Hopital Pellegrin Bordeaux 33076 France Details
CHU Bordeaux Bordeaux France Details
CHU Mondor Créteil France Details
Centre Oscar Lambret Lille France Details
Centre Léon Berard Lyon Lyon 69008 France Details
Hôpital Saint Louis Paris 75010 France Details
Hôpital Trousseau Paris 75012 France Details
CHU Toulouse Hopital des enfants Toulouse 31059 France Details
IUC Toulouse Toulouse 31059 France Details
CHU de nancy Vandœuvre-lès-Nancy 54500 France Details
Women'S and Children'S Nhs Foundation Trust Birmingham United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field